AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29526386 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 50
Study 29526386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 27537555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led tailored intervention
Number of subjects: 304
Study 27537555 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 304
Study 25434409 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 168
Study 25434409 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check by a nurse
Number of subjects: 168
Study 25434409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 168
Study 25434409 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 168
Study 25434409 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 168
Study 22210297 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anterior compartment reconstruction procedure
Number of subjects: 105
Study 22210297 — intervention group
Group type: COMPARATOR
Intervention: Prolift-a procedure
Number of subjects: 105
Study 20551820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair (n=16)
Number of subjects: 32
Study 20551820 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal‐preperitoneal hernia repair (n=16)
Number of subjects: 32
Study 18544179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 216
Study 18544179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and Dexamethasone
Number of subjects: 216
Study 15516488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTVV)
Number of subjects: 0
Study 15516488 — intervention group
Group type: COMPARATOR
Intervention: sTNFRI and II levels
Number of subjects: 0
Study 11196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based physical therapy (PT) intervention (education, exercise, and pain relief modalities) delivered by physiotherapists with advanced rheumatology training for 6 weeks.
Number of subjects: 127
Study 11196519 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group receiving the PT intervention between Weeks 6 to 12.
Number of subjects: 127
Study 9601678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic tones of different frequencies
Number of subjects: 0
Study 7989934 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy regimens and CNS prophylaxis regimens (intrathecal methotrexate alone or intrathecal methotrexate plus 18 Gy cranial irradiation)
Number of subjects: 1544
Study 7989934 — intervention group
Group type: COMPARATOR
Intervention: CNS prophylaxis regimens (intrathecal methotrexate alone or intrathecal methotrexate plus 18 Gy cranial irradiation)
Number of subjects: 1544
Study 2589907 — intervention group
Group type: EXPERIMENTAL
Intervention: Double wash swim-up technique
Number of subjects: 73
Study 178227 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 100
Study 178227 — intervention group
Group type: COMPARATOR
Intervention: Preexisting renal disease or cardiovascular disease
Number of subjects: 100
Study 178227 — intervention group
Group type: COMPARATOR
Intervention: Contrast volume
Number of subjects: 100
Study 30964697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Anterior Shoulder Stabilization (DAS)
Number of subjects: 24
Study 30964697 — intervention group
Group type: COMPARATOR
Intervention: Isolated Bankart repair
Number of subjects: 24
Study 29193019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/day orally on days 1-21; 28-day cycles)
Number of subjects: 254
Study 29193019 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (IC) therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine)
Number of subjects: 254
Study 29193019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 254
Study 26856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with soya beancurd (RWT)
Number of subjects: 15
Study 26856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with fish (RWF)
Number of subjects: 15
Study 26856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with egg white (RWE)
Number of subjects: 15
Study 26856623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with chicken (RWC)
Number of subjects: 15
Study 26856623 — intervention group
Group type: COMPARATOR
Intervention: Rice alone (control)
Number of subjects: 15
Study 24740312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg·kg(‐1)
Number of subjects: 20
Study 24740312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24740312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 22664647 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention via conference call
Number of subjects: 395
Study 22664647 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face (FTF) approach
Number of subjects: 395
Study 19707086 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention (daily messages regarding diabetes)
Number of subjects: 120
Study 19707086 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 120
Study 17526954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 528
Study 17526954 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 528
Study 15300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (mean dose 62 +/- 25 mg/day, adjusted to decrease resting heart rate by 25%)
Number of subjects: 161
Study 15300580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 15300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 161
Study 11123382 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 6
Study 11123382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 6
Study 11123382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MDMA and ethanol
Number of subjects: 6
Study 11123382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9642331 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 42
Study 9642331 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 42
Study 9642331 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 42
Study 8095150 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol (200 mg once daily)
Number of subjects: 16
Study 8095150 — intervention group
Group type: COMPARATOR
Intervention: diltiazem (60 mg three times daily)
Number of subjects: 16
Study 8095150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3688375 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BPD) at concentrations of 0.1 mg/ml, 0.05 mg/ml, 0.005 mg/ml, and 0.0005 mg/ml
Number of subjects: 0
Study 3688375 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide at concentrations of 0.25 mg/ml, 0.05 mg/ml, 0.025 mg/ml, and 0.00025 mg/ml
Number of subjects: 0
Study 3688375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol at concentrations of 20 mg/ml and 200 mg/ml
Number of subjects: 0
Study 3688375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29357963 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of highly educated mothers
Number of subjects: 715
Study 29357963 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of multiparous mothers
Number of subjects: 715
Study 29357963 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers with overweight/obesity
Number of subjects: 715
Study 27475099 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 42
Study 27475099 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 42
Study 24192662 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour induction
Number of subjects: 650
Study 24192662 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 650
Study 23887076 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal analgesic regimen (celecoxib, pregabalin, extended release oxycodone)
Number of subjects: 22
Study 23887076 — intervention group
Group type: COMPARATOR
Intervention: intravenous morphine
Number of subjects: 22
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: L84‐11 study
Number of subjects: 1846
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: L89‐12 study
Number of subjects: 1846
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: L92‐13 study
Number of subjects: 1846
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: L95‐14 study
Number of subjects: 1846
Study 20033052 — intervention group
Group type: COMPARATOR
Intervention: Intermediate- or high-dose methotrexate therapy
Number of subjects: 1846
Study 20033052 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg/m(2)
Number of subjects: 1846
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 1846
Study 20033052 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary brain tumors
Number of subjects: 1846
Study 18685526 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine + Protein (CP)
Number of subjects: 35
Study 18685526 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (C)
Number of subjects: 35
Study 18685526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 35
Study 16736065 — intervention group
Group type: EXPERIMENTAL
Intervention: New infant formula containing partially hydrolysed whey proteins and prebiotic oligosaccharides
Number of subjects: 267
Study 16736065 — intervention group
Group type: COMPARATOR
Intervention: Standard formula and simethicone (6 mg/kg twice a day)
Number of subjects: 267
Study 12745852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole cream
Number of subjects: 73
Study 12745852 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 73
Study 10965161 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (200 mg t.i.d.)
Number of subjects: 22
Study 10965161 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 8988072 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 0.5 to 80 mg/day
Number of subjects: 50
Study 8988072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7698138 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 42
Study 7698138 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (hydrochlorothiazide + triamterene)
Number of subjects: 42
Study 2956516 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty (n = 99)
Number of subjects: 386
Study 2956516 — intervention group
Group type: COMPARATOR
Intervention: Elective angioplasty (n = 98)
Number of subjects: 386
Study 29482588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 18 months
Number of subjects: 136
Study 29482588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 29354993 — intervention group
Group type: EXPERIMENTAL
Intervention: Joss stick moxibustion combined with pricking and cupping
Number of subjects: 70
Study 29354993 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medication (oral acyclovir, vitamin B1, mecobalamin tablets, and interferon injection)
Number of subjects: 70
Study 24406537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac pacing therapy
Number of subjects: 162
Study 24406537 — intervention group
Group type: COMPARATOR
Intervention: No cardiac pacing therapy (Control)
Number of subjects: 162
Study 22488880 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft combined with PRP (n = 85)
Number of subjects: 254
Study 22488880 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft alone (n = 101)
Number of subjects: 254
Study 22488880 — intervention group
Group type: COMPARATOR
Intervention: Allograft alone (n = 90)
Number of subjects: 254
Study 20562165 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface EMG biofeedback training (4 weeks)
Number of subjects: 65
Study 20562165 — intervention group
Group type: COMPARATOR
Intervention: Interdisciplinary rehabilitation (control group)
Number of subjects: 65
Study 17959524 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenetic field hyperthermia (EFH) combined with FOLFOX regimen
Number of subjects: 147
Study 17959524 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX regimen alone (Control group)
Number of subjects: 147
Study 16329383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon CustomCornea laser system
Number of subjects: 30
Study 16329383 — intervention group
Group type: COMPARATOR
Intervention: WaveLight Allegretto Wave laser system
Number of subjects: 30
Study 12477069 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact method for sample size and power determination
Number of subjects: 0
Study 12477069 — intervention group
Group type: COMPARATOR
Intervention: Asymptotic methods
Number of subjects: 0
Study 9507787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 120 mg or 180 mg
Number of subjects: 112
Study 9507787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/diltiazem ER alone
Number of subjects: 112
Study 9507787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/diltiazem ER
Number of subjects: 112
Study 9050491 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingo-oophorectomy
Number of subjects: 20
Study 9050491 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 20
Study 3275523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (2 mg for 3 weeks, followed by dose reductions and placebo)
Number of subjects: 45
Study 3275523 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (30 mg for 3 weeks, followed by dose reductions and placebo)
Number of subjects: 45
Study 3275523 — intervention group
Group type: COMPARATOR
Intervention: Methadone during hydromorphone challenge
Number of subjects: 45
Study 3275523 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine during hydromorphone challenge
Number of subjects: 45
Study 30422257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (5 atypical and 2 typical) for 6 weeks
Number of subjects: 3023
Study 30422257 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 3023
Study 30422257 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sequencing
Number of subjects: 3023
Study 28600189 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 140
Study 28600189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 26187714 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual biofeedback system
Number of subjects: 75
Study 26187714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiovisual biofeedback)
Number of subjects: 75
Study 23142150 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 46
Study 21393464 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 20
Study 21393464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 20
Study 21393464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18513524 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection devices during rescue PCI
Number of subjects: 93
Study 18513524 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 93
Study 16817525 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic feature ratings by participants
Number of subjects: 0
Study 14557155 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine vs Placebo
Number of subjects: 14
Study 14557155 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine vs Albuterol sulfate (salbutamol)
Number of subjects: 14
Study 11065068 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 264
Study 11065068 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 264
Study 11065068 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 264
Study 11065068 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding practices
Number of subjects: 264
Study 11065068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality
Number of subjects: 264
Study 9135750 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser guide for aiming the image intensifier
Number of subjects: 52
Study 1467901 — intervention group
Group type: EXPERIMENTAL
Intervention: Open drainage method, N=22
Number of subjects: 43
Study 1467901 — intervention group
Group type: COMPARATOR
Intervention: Capsulorrhaphy without drainage, N=21
Number of subjects: 43
Study 6363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/day in three doses for 10 days)
Number of subjects: 50
Study 6363660 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day in three doses for 10 days)
Number of subjects: 50
Study 6363660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Amoxicillin and Cefaclor)
Number of subjects: 50
Study 31449469 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy
Number of subjects: 70
Study 30409289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (40min, three times a week for four weeks)
Number of subjects: 40
Study 30409289 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 40
Study 26613286 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX4
Number of subjects: 0
Study 26613286 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 0
Study 23293845 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIN (strength‐trained one shoulder)
Number of subjects: 23
Study 23293845 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (no intervention)
Number of subjects: 23
Study 22391537 — intervention group
Group type: EXPERIMENTAL
Intervention: CMX001 (0.25 to 2.0 mg/kg single doses; 0.1 to 1.0 mg/kg multiple doses, 3 doses every 6 days)
Number of subjects: 0
Study 22391537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20528000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed maintenance-dose budesonide/formoterol
Number of subjects: 100
Study 20528000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable maintenance-dose budesonide/formoterol
Number of subjects: 100
Study 20528000 — intervention group
Group type: COMPARATOR
Intervention: Fixed maintenance-dose salmeterol/fluticasone propionate
Number of subjects: 100
Study 17585004 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day antibiotic therapy duration
Number of subjects: 88
Study 17585004 — intervention group
Group type: COMPARATOR
Intervention: 10-day antibiotic therapy duration
Number of subjects: 88
Study 17585004 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased days of diarrhea as a side effect
Number of subjects: 88
Study 17585004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing frequency (once daily vs. twice daily)
Number of subjects: 88
Study 17585004 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure rates
Number of subjects: 88
Study 16216004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 16216004 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 0
Study 12140400 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation inhibitors
Number of subjects: 32918
Study 12140400 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive agents
Number of subjects: 32918
Study 12140400 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol‐lowering medication
Number of subjects: 32918
Study 12140400 — intervention group
Group type: COMPARATOR
Intervention: Antidiabetic agents
Number of subjects: 32918
Study 10400003 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg daily for two weeks)
Number of subjects: 30
Study 10400003 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily for two weeks)
Number of subjects: 30
Study 10400003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7675968 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg SC)
Number of subjects: 0
Study 7675968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg PO)
Number of subjects: 0
Study 2188379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg three times daily
Number of subjects: 0
Study 2188379 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg daily
Number of subjects: 0
Study 2188379 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 0
Study 2188379 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 0
Study 2188379 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Simvastatin vs Bezafibrate
Number of subjects: 0
Study 6973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone 200 mg
Number of subjects: 0
Study 6973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 0
Study 6973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene 65 mg
Number of subjects: 0
Study 6973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone 100 mg
Number of subjects: 0
Study 6973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone
Number of subjects: 0